Table 1.
Summary of the retrieved studies investigating pre-treatment C-reactive protein to albumin ratio on survival in colorectal cancer patients
| Author | Year | Country | Tumor Location | Sample size | Gender, M:F | Age (years) | Stage | Treatment | Cut-off value | Outcome | HR | 95% CI | Follow-up time | Analysis | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ishizuka | 2016 | Japan | CRC | 627 | 400:227 | NA | 0–IV | Surgery | 0.038 | OS | 2.596 | 1.603–4.204 | NA | MV | 8 |
| Shibutani | 2016 | Japan | CRC | 99 | 57:42 | 63 (27–86) | IV | Chemotherapy | 0.183 | OS | 1.866 | 1.057–3.295 | 2.6–73.2 | MV | 8 |
| Shibutani | 2016 | Japan | CRC | 705 | 411:294 | 68 (26-90) | I–III | Surgery | 0.0278 |
DFS CSS |
1.503 1.672 |
1.054–2.143 1.012–2.764 |
NA | MV | 8 |
| Solaini | 2016 | UK | CRLM | 194 | 125:69 | 66 (59-73) | IV | Liver resection | 0.133 | OS | 2.04 | 1.26–3.3 | NA | UV | 7 |
| Haruki | 2017 | Japan | CRLM | 106 | 76:30 | 64.5 (39-87) | IV | Liver resection | 0.04 |
OS DFS |
2.559 1.731 |
1.420–4.613 1.087–2.758 |
NA | MV | 8 |
| Ide | 2017 | Japan | Rectum | 115 | 82:33 | 64 (33–83) | I–III | Surgery | 0.049 |
OS DFS |
5.09 4.98 |
2.31–11.58 2.34–11.14 |
65 (2–189) | MV | 8 |
| Dolan | 2018 | UK | Colon | 801 | 430:371 | NA | I–III | Surgery | 0.22 |
OS CSS |
1.84 1.76 |
1.49–2.26 1.31–2.35 |
NA | MV | 7 |
| Climent | 2019 | Ireland | CRC | 566 | 260:306 | 69.9 ± 12.3 | I–III | Surgery | 0.46 |
OS DFS |
1.84 1.73 |
1.1–3.1 0.8–3.3 |
NA | UV | 6 |
| Shibutani | 2019 | Japan | CRC | 40 | 25:15 | NA | IV | Chemotherapy | 0.122 |
OS PFS |
6.478 4.525 |
1.374–30.537 0.826–24.794 |
NA | MV | 8 |
| Sakamoto | 2020 | Japan | CRLM | 184 | 121:63 | 63.1 (25-94) | IV | Liver resection | 0.093 |
OS PFS |
2.82 1.62 |
1.63–4.72 1.02–2.49 |
NA | MV | 8 |
| Son | 2020 | Korea | CRC | 789 | 486:283 | NA | I–III | Surgery | 0.14 | OS | 1.97 | 1.47–2.64 | 91 (67–115) | UV | 7 |
| Suzuki | 2020 | Japan | Colon | 1303 | 689:614 | 65 (26-93) | II–III | Surgery | 0.02558 |
OS DFS |
1.8 1.28 |
1.24–2.68 0.99–1.66 |
60.2 (3–106) | MV | 8 |
| Ni | 2016 | china | CRC | 148 | 97:51 | NA | IV | Chemotherapy | 0.6712 | OS | 2.243 | 1.450–3.470 | NA | MV | 8 |
| Zhou | 2018 | china | CRC | 516 | 331:185 | NA | I–IV | Surgery | 0.07/0.08 |
OS DFS |
1.59 1.05 |
0.86–2.91 0.71–1.56 |
21.72 (2.11–118.72) | MV | 8 |
| Tominaga | 2016 | Japan | Colon | 136 | 79:57 | NA | III | Chemotherapy | 0.1 | DFS | 4.43 | 1.94–10.15 | NA | UV | 7 |
CRC colorectal cancer, CRLM colorectal cancer liver metastasis, MV multivariate, UV univariate, OS overall survival, DRS disease-free survival, CSS cancer-specific survival, PFS progression-free survival